Search clinical trials for: Toripalimab injection (JS001)

Total 10027 results

Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Ascentage Pharma Group Inc.

Recruiting

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Wan He

Recruiting

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC)

Stomach Neoplasms

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; Southwest Hospital, China; Daping Hospital...

Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sun Yat-sen University

Active, not recruiting

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) (RePASS)

Head and Neck Cancer

China
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Northern Jiangsu Province People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Radiotherapy | Immunotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
LaNova Medicines Zhejiang Co., Ltd.

Recruiting

A LM-302 Combined With Toripalimab Phase II Study

Gastric Cancer | Pancreatic Cancer

China
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Laryngeal Cancer | Hypopharyngeal Cancer

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Fudan University

Unknown

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Thyroid Cancer

China
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Oral Squamous Cell Carcinoma

China
Cancer Hospital of Guangxi Medical University

Recruiting

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...
Fudan University; First Affiliated Hospital of Fujian Medical University; Tianjin... and other collaborators

Recruiting

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (IMPORT)

Head and Neck Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Fudan University

Recruiting

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Renal Insufficiency | Solitary Kidney | Upper Urinary Tract Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, United States, Taiwan, Turkey, Georgia
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China

3

Subscribe